Production of alpha 1,3-galactosyltransferase-deficient pigs.
about
Precision editing of large animal genomesGenetic manipulation in pigsCreating genetically modified pigs by using nuclear transferTissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerateSpecific genetic modifications of domestic animals by gene targeting and animal cloningCreation of non-human primate neurogenetic disease models by gene targeting and nuclear transferReport from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell ReplacementUse of genetically-engineered pig donors in islet transplantationCancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionKidney xenotransplantationImmune modulation in xenotransplantationAnti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefitsCardiac xenotransplantation: progress and challengesTransgenesis for pig modelsImmunobiological barriers to xenotransplantationHumans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantationHighly efficient CRISPR/Cas9-mediated transgene knockin at the H11 locus in pigsGenetically-engineered pig-to-baboon liver xenotransplantation: histopathology of xenografts and native organsThe Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevanceFunctionally important glycosyltransferase gain and loss during catarrhine primate emergenceBioprosthetic heart valves of the futureEfficient generation of a biallelic knockout in pigs using zinc-finger nucleasesNatural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?The unfinished legacy of liver transplantation: emphasis on immunology.Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation.Electroporation advances in large animals.Anti-pig antibody levels in non-human primates of various origin.Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery.Identification of an anti-idiotypic antibody that defines a B-cell subset(s) producing xenoantibodies in primates.Gene targeting in adult rhesus macaque fibroblasts.The anti-non-gal xenoantibody response to xenoantigens on gal knockout pig cells is encoded by a restricted number of germline progenitorsCoagulation dysregulation as a barrier to xenotransplantation in the primateHepatic function after genetically engineered pig liver transplantation in baboons.Clinical pig liver xenotransplantation: how far do we have to go?Pathologic characteristics of transplanted kidney xenografts.Immunobiology of liver xenotransplantation.Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation.Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.Further evidence for sustained systemic inflammation in xenograft recipients (SIXR).Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs
P2860
Q24611750-12A46B6E-FBEF-47C3-8F74-7A2C4E0DB1CAQ24654314-E89012E5-1476-47DC-8798-BF08D97D871AQ24798575-AD6BBC1F-B23F-40A0-B6BE-E6D61BE67A18Q24799127-B43ED428-A1C4-4560-8807-F765FCFBF145Q24801067-02B10F14-5E8E-4892-BBA3-AB4C72D6E4D6Q24803689-557E6AD1-D469-4214-99F4-68BBB9D9EBD7Q26769878-13D8408C-78D1-4940-9C24-051DC3E5DB9AQ26771395-90959AD4-1CD7-4777-9535-A8A05E31093DQ26777542-0AADA90C-F3E5-4AB9-9139-E2C21E65A4B4Q26822638-499AF761-EAE1-4BF4-BC01-21E1021AF58FQ26826905-B425CDBA-65DB-4F55-BF6F-A0C53E508B60Q27021788-E2AF693F-F3BA-43E0-8FF6-C310C624FD2DQ27024045-A4E10EE2-30FB-4E63-A54C-47B31E8BF0D2Q28067280-EA8D2761-6C1B-4B14-AFF1-93C82949A103Q28081993-579875C6-3B72-40B9-B9B9-ABD9F1E04019Q28119060-1B5B6E76-1B5D-4CF5-A687-BAB08E96BDB0Q28267505-10A8AE71-F982-47DE-A06D-AB1AABE5910EQ28732872-581444D8-FC5F-41F1-9FFA-4B1D247FE5FEQ28755302-AF415E3E-34C2-46FA-8249-F5E1EB200557Q28763873-59EB5CA1-C0D6-4720-A46A-92D6AE8F999CQ28829371-10CA02C7-CBCA-4A93-998F-E62F5F589BF2Q29042244-012D453C-6037-462A-826F-42E537C93813Q30248270-17B55553-B041-4944-8DA8-09A6A4BB9747Q30352760-B79CAB5A-98DA-4A22-B354-AF7855426850Q30430008-F25AA746-2F46-442F-A9D7-B68258E3304CQ30476834-A3F96BDD-882B-4C83-8DB7-C1C8F020F06AQ31078985-614C0353-AF54-471E-9E1D-CE9BB972AEBDQ31139787-E9390DEC-0267-4F84-80A5-25EC7892B894Q33301575-45CEAE32-B11C-4950-B1F8-D0852FD2288CQ33325792-05942641-A6CE-49F1-A28B-A7ECB9851A6EQ33356739-BFADAB2D-7FC3-4824-BB73-7736B7D90D75Q33381973-C4566971-C766-4E94-990C-9644507A6C91Q33390545-E8635A7F-6670-40A7-9B2A-5687857B643CQ33395889-197FCCC6-8441-4C8E-AF4B-A362863A0807Q33398429-D7E5C9B9-EFC5-48A9-AFA2-4DCEDC11F280Q33403888-EACF7F1E-8F23-4BEE-9247-B951B4B66289Q33415141-6D627A52-FDDB-486D-AD43-7F5E0AD94621Q33421736-738AA414-F43F-4C10-A852-3D30B4B85419Q33425296-E729CEF3-1679-4A39-ABCB-6D74AC3EDF56Q33494564-65ECE94F-204A-4D7F-9A14-A54C3955F094
P2860
Production of alpha 1,3-galactosyltransferase-deficient pigs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@ast
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@en
type
label
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@ast
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@en
prefLabel
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@ast
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@en
P2093
P2860
P356
P1433
P1476
Production of alpha 1,3-galactosyltransferase-deficient pigs.
@en
P2093
Amy S Garst
Ashley E Lamborn
Carol J Phelps
Chihiro Koike
David L Ayares
Irina A Polejaeva
Jeff A Monahan
Jeremy Boone
Kevin D Wells
Marilyn Moore
P2860
P304
P356
10.1126/SCIENCE.1078942
P407
P577
2002-12-19T00:00:00Z